Soleno Therapeutics Inc

Soleno Therapeutics Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for rare diseases. Its lead product is VYKAT XR (diazoxide choline) extended-release tablets, an oral treatment for hyperphagia in adults and children with Prader-Willi syndrome, with operations centered in the United States and potential expansion into other major markets.

6,0 %

98,6 %

11,0 %

5.80

5.55

— Soleno Therapeutics Inc
%
Commercial pharmaceutical product100% VYKAT XR prescription sales for hyperphagia in Prader-Willi syndrome.
Drug development pipeline0% Research and regulatory work supporting future rare-disease therapeutics.
Patient access and support services0% Education, financial assistance, and onboarding support via SOLENO ONE.

The company sells primarily to specialty pharmacy channels that dispense VYKAT XR pursuant to physician prescriptions...

  • Specialty pharmacy channelprimary

    Buys VYKAT XR and dispenses it to patients under prescription; critical for commercialization.

  • Physicians and prescribersprimary

    Recommend and prescribe VYKAT XR for eligible PWS patients based on clinical need.

  • Patients with Prader-Willi syndromeprimary

    Use the therapy to address hyperphagia and related disease burden.

  • Payers and reimbursement decision-makerssecondary

    Influence access through formulary placement, coverage, and patient out-of-pocket cost.

  • Caregivers and patient advocatessecondary

    Support treatment initiation, adherence, and navigation of access programs.

Soleno is headquartered in Redwood City, California and conducts its core commercial and operational activities in the...

  • •Headquartered in Redwood City, California
  • •Primary commercial market is the United States
  • •API stored at third-party facilities in the U.S.
  • •U.S. CMOs manufacture, package, and label VYKAT XR
  • •Europe and Japan are potential future commercialization markets

The company’s strategy is centered on building VYKAT XR into a commercial rare-disease product and expanding physician,...

01
Commercialize VYKAT XR in the U.S.short-term

The company’s value creation depends on physician adoption, patient access, and prescription growth.

02
Build commercial infrastructureshort-term

A rare-disease launch requires targeted sales, medical affairs, and support capabilities.

03
Expand internationally through partners or direct entrymedium-term

Ex-U.S. markets could broaden the addressable patient base while limiting execution risk through partnerships.

04
Protect supply and manufacturing continuityshort-term

Commercial availability depends on third-party API, CMO, and logistics execution.

Soleno is highly dependent on the commercial success of a single approved product, which concentrates execution,...

critical

Single-product dependence

Revenue and enterprise value are tied to VYKAT XR adoption and durability.

Scope
VYKAT XR
Materiality
high
high

Market acceptance and reimbursement risk

Physicians, patients, caregivers, and payers must accept the therapy for commercial success.

Scope
U.S. launch
Materiality
high
high

Manufacturing and supply-chain disruption

The company relies on third-party CMOs, 3PLs, and external API storage.

Scope
Commercial supply
Materiality
high
high

Intellectual property and competitive pressure

Competing PWS therapies or broader appetite-suppression drugs could limit share.

Scope
Prader-Willi syndrome market
Materiality
medium
medium

International regulatory and partner execution

Ex-U.S. commercialization depends on later strategic decisions and local approvals.

Scope
Europe, Japan, other markets
Materiality
medium
Revenue reserves under ASC 606
Can materially change product revenue and gross-to-net deductions
Contingent consideration fair value
Can create volatility in operating expenses and net income
Stock-based compensation
Affects SG&A and R&D expense trends
Fair value of marketable securities and financial instruments
Can affect other income/expense and balance sheet values

SOLIGENIX, INC.

SNGX · Pharmaceutical Preparations

Monopar Therapeutics

MNPR · Pharmaceutical Preparations

Rallybio Corp

RLYB · Pharmaceutical Preparations

X4 Pharmaceuticals, Inc

XFOR · Biological Products, (No Diagnostic Substances)

Rezolute, Inc.

RZLT · Pharmaceutical Preparations

ARROWHEAD PHARMACEUTICALS, INC.

ARWR · Pharmaceutical Preparations

: 29/04/2026